dina,md (@drbmsg) header
dina,md (@drbmsg) profile picture

Gen./Public Health MD,FPAMS-AN MPH-SEAMEO ret.DOH-Hosp HIV/AIDS Core Team leader; MSIII Chief TrainingOffcr.;OIC Chief of Clinics; CSEE/CESE-CareerExec.Service

PH H/A Education & Awareness
Joined May 2020
Photo by dina,md (@drbmsg)Photo by dina,md (@drbmsg)Photo by dina,md (@drbmsg)Photo by dina,md (@drbmsg)Photo by dina,md (@drbmsg)Photo by dina,md (@drbmsg)Photo by dina,md (@drbmsg)Photo by dina,md (@drbmsg)Photo by dina,md (@drbmsg)Photo by dina,md (@drbmsg)
Pictures of old, showing that the love & care for the "red ribbon" has taken roots in our team of hospital health workers & today, even apart from one another, time has not erased in me the mission to continue getting connected to present communities. MERRY CHRISTMAS, HAPPY 2022!
2
44
Hello, holidays are here again for everyone to think different activities. many for sure are thinking to travel. Here are reminders: Have a complete dose of vaccination; CD4 not below 200 preferred; see travel requirements; prepare adequate medicine supplies, add extra; label->
3
19
1
56
and place in container. Inform provider of planned travel, get referral clinic. get info of health status of destination; observe health protocol; careful w/ water & food; and take along emergency meds. Have time to enjoy your family / social groups. Take good care, stay safe.:)
1
18
2021 WORLD AIDS DAY Another year of CELEBRATION! Celebrating not the disease condition but the SPIRIT of the PLHIV/PLWH in living up with faith, courage and strong will to overcome all struggles and hoping that the BEST is COMING! Congratulations! Let us also congratulate all ->
5
107
3
256
2. countries that support PLWH's health care progs/benefits PLWHs. This is a prelude to our GOAL: END ALL INEQUALITIES; END AIDS. Better ART, Better conditions(work,travel, educ., healthcare, acceptance); Hope-filled,Promising Clin.trials for Cure - WELCOME! HPI World AIDS DAY!
1
1
30
Crea Elevation: One of the concerns brought to my attention is the elevation of blood creatinine w/ shifting LTE to DTG med. ex. a 1.8 mg/dL. (Normal level is 0.9-1.5 male & 0.6-1.1 in female, adults) This shouldn't cause much worry as some ARV drugs have this initial effect. ->
5
19
1
55
2. It will normalize when the body adjusts to it; though if prolonged, or getting higher, it may lead to kidney damage. To prevent crea elevation, always have adequate hydration, 2-3L/day; a glassful water w/ ARV dose. This helps absorb & distribute drug by blood circulation ->
1
2
16
3. & also helps eliminate excesses/toxins thru the urine, thus helps reduce drug side effects. Other factors that may cause crea elev.: are high protein diet(red meat);excessive physical exercises. Advise to eat more vegies,legume protein; do light exercises, less muscle work. TC
3
15
Happy Sunday! It is nice to share info that one of our co-Advocates, CouragePinas serves the concerns of some members of our community in STI consults & treatment (ex. wart tx & others), HIV testing w/ linkages made to other treatment Hubs. Pls. refer to their page: @CouragePinas
2
20
DRUG RESISTANCE - CAUSES and PREVENTION HIV drug resistance means that the infecting HIV virus is able to replicate or mutate even when one is on HIV medication. Causes: 1- Poor or non-adherence to ART, that is, missing scheduled doses; also, improper taking of ART as in with ->
7
89
2
162
4. taken for ART; but 1 or 2 of the other drugs can still suppress the "resistant variant". These ARVs can individually act against multiple variants. 3- Early exposure to HIV drugs as in the use of PrEP. It is impt. to inform one's care-provider of his condition & meds. in-use.
2
2
15
3. This means that the infecting HIV virus is a resistant virus from a PLHIV under ART. This is the reason that Resistance Test is advised before starting ART to be guided on the choice of ART regimen. Developing HIV drug resistance doesn't mean ART failure. 3 drug combi. are ->
1
2
14
2. or w/out food. Note: When a dose is missed on time schedule, take it as soon as it is remembered; but if it is close to the time of the next dose, just wait to take the next dose but don't double the dose; then continue the regular sched. 2- Transmitted HIV drug resistance ->
6
15
VIRAL BLIP When viral load that is undetectable (UD) for a time becomes detectable, with increased VL, then returns back to UD level, this is a "viral blip". It is usually not a concern as this can only be a laboratory error in the test. There may be true VL increase due to ->
1
29
3
56
2. stress during illness or after a vaccine received. Blips also happen when one's medication is temporarily discontinued / delayed due to long non-availability. But with some improved qualities of new ARV medications, temporary discontinuance even for weeks may not cause a blip.
3
1
1
6
RESISTANCE TEST Resistance Test is done prior to starting ART to find out if the infecting virus is a drug-resistant virus. This will guide to the choice of ARV drugs to use. It is done also during ART when there seems to be treatment failure. 2 types of Resistance Tests: ->
3
28
60
3. is hard to suppress. Resistance test can't be done with VL below 500; but the GenoSure Archive test can be used where VL is below 500 or is suppressed. Archive resistance is resistance developed in the past not detected by the standard resistance tests.
10
2. Genotype test - will look for mutations or changes in the gene structure of the virus causing the drug resistance. Phenotype Test - will check on the ability of the infecting virus to reproduce or replicate or multiply even under ART, showing the virus is not suppressed or ->
1
14
Monitoring ART Measure of the Viral Load (VL) is the best indicator of HIV treatment success or failure. VL should be Undetectable (UD) within 4-6 months of starting therapy (ART); faster within 4-8 weeks with the integrase-inhibitor-based regimen. When VL does not decrease, ->
2
33
1
73
2. or if it becomes detectable after it has been UD, these may be signs of treatment failure. If VL is 200 and rising, it could mean a developing resistance. Your healthcare provider will assess for ART failure or drug resistance or will be considering drug replacement.
1
1
14